Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03894618 · OUTCOME

Recommended Phase 2 Dose for SL-279252

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas · Source last updated 2025-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg/kg
Interval / dispersion
Not reported
Time frame
Approximately 32 months

What was measured

Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects

Groups in this outcome

SL-279252

SL-279252 received in Schedule 1 or Schedule 2

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
SL-27925249

Reported measurements

Source class 1
Values in mg/kg · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
SL-279252NANot reportedNot reportedNot reportedMTD/RP2D not achieved in this study
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        MTD/RP2D not achieved in this study
        group Id
        OG000
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      49
    units
    Participants
description
Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects
groups
  1. description
    SL-279252 received in Schedule 1 or Schedule 2
    id
    OG000
    title
    SL-279252
param Type
NUMBER
reporting Status
POSTED
time Frame
Approximately 32 months
title
Recommended Phase 2 Dose for SL-279252
type
SECONDARY
unit Of Measure
mg/kg

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice